Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.
Fourteen patients undergoing strongly emetic cancer chemotherapy received a total of 33 continuous infusions of high-dose metoclopramide to prevent nausea and vomiting. Metoclopramide 2 mg/kg was given as an i.v. infusion over 15 min followed by continuous infusion over 13 h of 5 mg/kg. The antiemetic response could be evaluated in 12 patients receiving their first continuous metoclopramide infusion. Six patients were partly or completely protected from acute gastrointestinal disturbances. Three patients experienced a short-lived extrapyramidal syndrome during the continuous metoclopramide infusions. Other side effects observed were mild. Thus, high-dose metoclopramide given as a continuous infusion is an effective antiemetic treatment in patients receiving cancer chemotherapy.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D008787:Metoclopramide